RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PDS Biotechnology Stock

PDS Biotechnology Equity 2025

PDS Biotechnology Equity

19 M USD

Ticker

PDSB

ISIN

US70465T1079

WKN

A2PF3F

In 2025, PDS Biotechnology's equity was 19 M USD, a -27.27% increase from the 26.13 M USD equity in the previous year.

PDS Biotechnology Aktienanalyse

What does PDS Biotechnology do?

PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing PDS Biotechnology's Equity

PDS Biotechnology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding PDS Biotechnology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating PDS Biotechnology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

PDS Biotechnology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in PDS Biotechnology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about PDS Biotechnology stock

What is the equity of PDS Biotechnology this year?

PDS Biotechnology has equity of 19 M USD this year.

What was the equity of PDS Biotechnology compared to the previous year?

The equity of PDS Biotechnology has increased/decreased by -27.27% decreased compared to the previous year.

What impact does a high equity have on investors of PDS Biotechnology?

A high equity is advantageous for investors of PDS Biotechnology as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of PDS Biotechnology?

A low equity can be a risk for investors of PDS Biotechnology, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of PDS Biotechnology affect the company?

An increase in equity of PDS Biotechnology can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of PDS Biotechnology affect the company?

A reduction in equity of PDS Biotechnology can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of PDS Biotechnology?

Some factors that can affect the equity of PDS Biotechnology include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of PDS Biotechnology so important for investors?

The equity of PDS Biotechnology is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can PDS Biotechnology take to change the equity?

To change equity, PDS Biotechnology can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does PDS Biotechnology pay?

Over the past 12 months, PDS Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PDS Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of PDS Biotechnology?

The current dividend yield of PDS Biotechnology is .

When does PDS Biotechnology pay dividends?

PDS Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PDS Biotechnology?

PDS Biotechnology paid dividends every year for the past 0 years.

What is the dividend of PDS Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PDS Biotechnology located?

PDS Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von PDS Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PDS Biotechnology from 10/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/15/2025.

When did PDS Biotechnology pay the last dividend?

The last dividend was paid out on 10/15/2025.

What was the dividend of PDS Biotechnology in the year 2024?

In the year 2024, PDS Biotechnology distributed 0 USD as dividends.

In which currency does PDS Biotechnology pay out the dividend?

The dividends of PDS Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The PDS Biotechnology stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von PDS Biotechnology

Our stock analysis for PDS Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PDS Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.